News headlines about Covance (NYSE:CVD) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Covance earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave headlines about the healthcare company an impact score of 46.9957254615297 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Covance (NYSE CVD) remained flat at $$107.07 on Wednesday. The stock has a market capitalization of $6,060.00 and a PE ratio of 33.05.

COPYRIGHT VIOLATION NOTICE: This report was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://theolympiareport.com/2018/02/14/covance-cvd-receives-news-impact-score-of-0-06.html.

Covance Company Profile

Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.

Insider Buying and Selling by Quarter for Covance (NYSE:CVD)

Receive News & Ratings for Covance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance and related companies with MarketBeat.com's FREE daily email newsletter.